Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572623 | 1.00 | MME (0.50) | MMEACETP53CPA1ACE2 | |
| SCHEMBL7725288 | 0.81 | MME (0.52) | MMEACETP53CPA1ACE2 | |
| SCHEMBL7362168 | 0.81 | MME (0.52) | MMEACETP53CPA1ACE2 | |
| SCHEMBL9652457 | 0.81 | MME (0.52) | MMEACETP53CPA1ACE2 | |
| SCHEMBL21000307 | 0.80 | MME (0.52) | MMEACETP53CPA1ACE2 | |
| SCHEMBL26654282 | 0.80 | MME (0.47) | MMEACETP53CPA1ACE2 | |
| SCHEMBL6823967 | 0.80 | MME (0.47) | MMEACETP53CPA1ACE2 | |
| SCHEMBL23142762 | 0.77 | MME (0.48) | MMEACECPA1ACE2RAB9A | |
| SCHEMBL13165106 | 0.77 | MME (0.48) | MMEACECPA1ACE2RAB9A | |
| SCHEMBL21375005 | 0.77 | ACE (0.59) | MMEACECPA1ACE2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0804181-A4 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES INC (US) | 2005-02-02 | — | — | EP | claimed |
| EP-0804181-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | Cellular Sciences, Inc. (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1997010818-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES, INC. (US) | 1997-03-27 | — | — | WO | claimed |
| US-20070054021-A1 | Flavour modulating substance | QUEST INTERNATIONAL SERVICES B.V. (NL) | 2007-03-08 | — | — | US | disclosed |
| EP-0804181-A4 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6482856-B1 | Method and composition for treating mammalian disease caused by inflammatory response | CELLULAR SCIENCES, INC. | 2002-11-19 | — | — | US | disclosed |
| US-5952384-A | CONTACTING THE MAMMALIAN CELL WITH AN INFLAMMATORY MEDIATOR SELECTED FROM THE GROUP CONSISTS OF PYRUVATE AND PYRUVATE PRECURSOR CAPABLE OF REDUCING UNDESIRED INFLAMMATORY RESPONSE AND IS ANTIOXIDANT | CELLULAR SCIENCES, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5939459-A | CONTACTING WITH AN INFLAMMATORY MEDIATOR SELECTED FROM THE GROUP CONSISTING OF PYRUVATE AND A PYRUVATE PRECURSOR AND IS PRESENT IN AN AMOUNT CAPABLE OF REDUCING THE UNDESIRED INFLAMMATORY RESPONSE AND IS AN ANTIOXIDANT | CELLULAR SCIENCES INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5798388-A | ANTIOXIDANT, ANTIASTHMA, ADMINISTERING PYRUVATE WITHOUT ALBUTEROL | CELLULAR SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| EP-0804181-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | Cellular Sciences, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997010818-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES, INC. (US) | 1997-03-27 | — | — | WO | disclosed |